Gilead Sciences, Inc. $GILD Stock Position Lifted by Orion Porfolio Solutions LLC

Orion Porfolio Solutions LLC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 100,321 shares of the biopharmaceutical company’s stock after buying an additional 8,843 shares during the quarter. Orion Porfolio Solutions LLC’s holdings in Gilead Sciences were worth $11,136,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of GILD. Corundum Trust Company INC purchased a new position in shares of Gilead Sciences during the 3rd quarter valued at $26,000. Howard Hughes Medical Institute acquired a new stake in Gilead Sciences during the second quarter valued at $30,000. MTM Investment Management LLC boosted its position in Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares during the last quarter. Kilter Group LLC purchased a new position in Gilead Sciences in the second quarter valued at about $33,000. Finally, Millstone Evans Group LLC grew its stake in Gilead Sciences by 58.7% in the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 118 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on GILD. Rothschild & Co Redburn raised their price target on Gilead Sciences from $159.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Leerink Partners increased their price objective on Gilead Sciences from $146.00 to $148.00 and gave the stock an “outperform” rating in a report on Wednesday, February 11th. BMO Capital Markets raised their price objective on shares of Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday, January 26th. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Finally, Royal Bank Of Canada raised their price target on shares of Gilead Sciences from $103.00 to $118.00 and gave the company a “sector perform” rating in a report on Wednesday, February 11th. Twenty-three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $156.72.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the sale, the chief executive officer directly owned 642,308 shares in the company, valued at approximately $92,999,775.32. The trade was a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the transaction, the director owned 8,920 shares of the company’s stock, valued at $1,101,620. The trade was a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 309,280 shares of company stock worth $43,935,470 over the last quarter. 0.27% of the stock is owned by company insiders.

Gilead Sciences Trading Down 2.1%

Shares of Gilead Sciences stock opened at $145.14 on Friday. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The company’s fifty day simple moving average is $137.91 and its 200-day simple moving average is $125.56. The company has a market cap of $180.18 billion, a price-to-earnings ratio of 21.44, a PEG ratio of 1.94 and a beta of 0.37. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a $0.82 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.3%. Gilead Sciences’s payout ratio is currently 46.68%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.